Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 5/20 | 0.45 |
| ▸ | OPRD1 known ✓ | P41143 | 2/20 | 0.45 |
| ▸ | OPRK1 known ✓ | P41145 | 2/20 | 0.45 |
| ▸ | TACR1 known ✓ | P25103 | 1/20 | 0.44 |
| ▸ | NPFFR1 | Q9GZQ6 | 2/20 | 0.45 |
| ▸ | NPFFR2 | Q9Y5X5 | 2/20 | 0.45 |
| ▸ | FKBP4 | Q02790 | 1/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29442961 | 0.99 | OPRM1 (0.45) | OPRM1NPFFR1NPFFR2OPRD1OPRK1 | |
| SCHEMBL7586649 | 0.97 | OPRM1 (0.47) | OPRM1NPFFR1NPFFR2OPRD1OPRK1 | |
| SCHEMBL30561151 | 0.97 | OPRM1 (0.47) | OPRM1NPFFR1NPFFR2OPRD1OPRK1 | |
| SCHEMBL29387566 | 0.88 | F2 (0.57) | OPRM1NPFFR1NPFFR2OPRD1OPRK1 | |
| SCHEMBL497331 | 0.87 | FKBP4 (0.43) | OPRM1NPFFR1NPFFR2OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL7752557 | 0.86 | FKBP4 (0.48) | OPRM1NPFFR1NPFFR2OPRD1OPRK1 | |
| SCHEMBL5704652 | 0.86 | FKBP4 (0.48) | OPRM1NPFFR1NPFFR2OPRD1OPRK1 | |
| SCHEMBL6049428 | 0.85 | NTSR2 (0.48) | OPRM1NPFFR1NPFFR2OPRD1 | |
| Acetic Acid SCHEMBL3281925 | 0.85 | FKBP4 (0.48) | OPRM1OPRD1OPRK1TACR1FKBP4 | |
| SCHEMBL30831830 | 0.85 | F2 (0.59) | OPRM1NPFFR1NPFFR2OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114921447-B | Preparation method of enzyme reagent and prothrombin time detection card containing enzyme reagent | 可孚医疗科技股份有限公司 | 2023-12-12 | — | — | CN | claimed |
| CN-116718776-A | Detect alpha 2 Macroglobulin kit | 希肯生物技术(苏州)有限公司 | 2023-09-08 | — | — | CN | claimed |
| CN-112662735-B | Antithrombin III activity determination kit and preparation method thereof | 北京美创新跃医疗器械有限公司 | 2022-10-14 | — | — | CN | claimed |
| US-12618841-B2 | Methods of diagnosing malignant diseases | ST INNOVATIVE DIAGNOSTICS LTD (IL) | 2026-05-05 | — | — | US | disclosed |
| CN-118239923-A | Compounds useful as inhibitors of factor XIIa, pharmaceutical compositions and uses thereof | 合肥工业大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-115677850-B | Hirudo gene mutant hirudin with strong anticoagulation activity and preparation method thereof | 王大勇 | 2024-03-08 | — | — | CN | disclosed |
| CN-115572329-B | Poecilobdella manillensis gene recombinant hirudin with slower activity enhancement metabolism and preparation method thereof | 王大勇 | 2024-02-06 | — | — | CN | disclosed |
| CN-114921447-B | Preparation method of enzyme reagent and prothrombin time detection card containing enzyme reagent | 可孚医疗科技股份有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-116908476-A | Method for diagnosing malignant disease | ST创新诊断有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-110234997-B | Method for diagnosing malignant disease | ST创新诊断有限公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20230109120-A1 | METHODS OF DIAGNOSING MALIGNANT DISEASES | ST INNOVATIVE DIAGNOSTICS LTD (IL) | 2023-04-06 | — | — | US | disclosed |
| CN-115677850-A | Hirudin with strong anticoagulation activity and gene mutation and preparation method thereof | 王大勇 | 2023-02-03 | — | — | CN | disclosed |
| CN-115586179-A | Kit for determining activity of antithrombin III and application thereof | 深圳市帝迈生物技术有限公司 | 2023-01-10 | — | — | CN | disclosed |
| CN-115572329-A | Poecilobdella manillensis gene recombinant hirudin with slow activity enhancement and metabolism and preparation method thereof | 王大勇 | 2023-01-06 | — | — | CN | disclosed |
| CN-112662735-B | Antithrombin III activity determination kit and preparation method thereof | 北京美创新跃医疗器械有限公司 | 2022-10-14 | — | — | CN | disclosed |
| CN-114921447-A | Preparation method of enzyme reagent and prothrombin time detection card containing enzyme reagent | 可孚医疗科技股份有限公司 | 2022-08-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12618841-B2 | Methods of diagnosing malignant diseases | FGB, F2, TFPI2 | OPRM1 4826/4885OPRD1 4793/4885OPRK1 4746/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.